Laboratory and Imaging Workup for PCOS
All women being evaluated for PCOS should have TSH, prolactin, and 17-hydroxyprogesterone (17-OHP) measured to exclude mimicking disorders, along with assessment of androgen levels (total testosterone and sex hormone-binding globulin) and pelvic ultrasound to document polycystic ovarian morphology when needed to meet diagnostic criteria. 1
Essential Laboratory Tests
The diagnostic workup follows a structured approach based on the Rotterdam criteria, which requires meeting 2 of 3 features: androgen excess, ovulatory dysfunction, or polycystic ovaries 1.
Mandatory Screening Tests (All Patients)
These tests exclude conditions that mimic PCOS and must be performed in every patient:
- TSH - excludes thyroid disease presenting with menstrual irregularity
- Prolactin - excludes hyperprolactinemia (can present with amenorrhea or hirsutism)
- 17-hydroxyprogesterone (17-OHP) - excludes nonclassic congenital adrenal hyperplasia (found in 1.5-6.8% of patients with androgen excess) 1
Androgen Assessment
When hyperandrogenism is not clinically obvious, measure:
- Total testosterone
- Sex hormone-binding globulin (SHBG) - allows calculation of free androgen index
- Free or bioavailable testosterone (optional, enhances diagnostic accuracy) 2
Note that you do not need universal androgen screening if the patient already meets two diagnostic criteria clinically 1. However, recent evidence shows that standardizing the initial biochemical panel reduces diagnostic delays significantly - patients with comprehensive testing at first venepuncture had median time to diagnosis of 29 days versus 255 days for those requiring multiple testing episodes 3.
Additional Hormonal Tests
- LH and FSH - While an LH/FSH ratio >2:1 occurs in 55% of PCOS patients 4, this is not required for diagnosis and has limited sensitivity and specificity 5
- Anti-Müllerian hormone (AMH) - Not required for diagnosis per guidelines 1, but recent research demonstrates AMH alone has good diagnostic accuracy (AUROC 0.884), and combining AMH with ovarian volume improves performance (AUROC 0.906) 2
Imaging
Pelvic Ultrasound
Transvaginal ultrasound is the gold standard for documenting polycystic ovarian morphology, defined as:
- At least one ovary with ≥12 follicles measuring 2-9 mm, OR
- Ovarian volume >10 mL
- In the absence of a dominant follicle >10 mm 1
Important caveats:
- Ultrasound is NOT required if the patient already meets two diagnostic criteria clinically (hyperandrogenic chronic anovulation) 1
- Total ovarian area >5.5 cm² is an alternative morphologic criterion 5
- Recent data shows ovarian volume combined with AMH provides excellent diagnostic accuracy 2
Selective Additional Testing
For patients with atypical presentations, consider:
- 24-hour urinary free cortisol - if Cushing's syndrome suspected (proximal muscle weakness, central obesity)
- Dehydroepiandrosterone sulfate (DHEA-S) - if virilization present
- IGF-1 - if acromegaly suspected (frontal bossing) 1
Metabolic Screening
While not required for diagnosis, assess metabolic risk:
- Oral glucose tolerance test with insulin levels - evaluates insulin resistance
- Lipid panel
- Body mass index and waist-hip ratio 6
Practical Algorithm
- Document clinical features: menstrual irregularity pattern, hirsutism (Ferriman-Gallwey score), acne
- Order comprehensive initial panel (single venepuncture): TSH, prolactin, 17-OHP, total testosterone, SHBG, LH, FSH 3
- Perform pelvic ultrasound if needed to meet diagnostic criteria
- Add selective tests only for atypical presentations
Critical pitfall: Ordering incomplete initial testing leads to diagnostic delays of 6-8 months 3. The most efficient approach uses a standardized panel at first evaluation rather than sequential testing.